Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.88 Billion TWD | -0.77% |
| 2022 | 3.91 Billion TWD | 7.72% |
| 2021 | 3.63 Billion TWD | -29.15% |
| 2020 | 5.12 Billion TWD | 31.83% |
| 2019 | 3.88 Billion TWD | 4.67% |
| 2018 | 3.71 Billion TWD | 4.24% |
| 2017 | 3.56 Billion TWD | -5.39% |
| 2016 | 3.76 Billion TWD | -14.25% |
| 2015 | 4.39 Billion TWD | 165.89% |
| 2014 | 1.65 Billion TWD | 17.33% |
| 2013 | 1.4 Billion TWD | 25.02% |
| 2012 | 1.12 Billion TWD | 14.41% |
| 2011 | 984.4 Million TWD | 4.58% |
| 2010 | 941.33 Million TWD | -16.64% |
| 2009 | 1.12 Billion TWD | 34.18% |
| 2008 | 841.6 Million TWD | 11.77% |
| 2007 | 752.99 Million TWD | -4.18% |
| 2006 | 785.84 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.55 Billion TWD | -8.45% |
| 2024 Q2 | 4.17 Billion TWD | 17.48% |
| 2023 Q1 | 3.52 Billion TWD | -9.88% |
| 2023 Q3 | 3.12 Billion TWD | -37.86% |
| 2023 Q2 | 5.03 Billion TWD | 42.68% |
| 2023 FY | 3.88 Billion TWD | -0.77% |
| 2023 Q4 | 3.88 Billion TWD | 24.17% |
| 2022 FY | 3.91 Billion TWD | 7.72% |
| 2022 Q1 | 3.18 Billion TWD | -12.4% |
| 2022 Q4 | 3.91 Billion TWD | 20.63% |
| 2022 Q3 | 3.24 Billion TWD | -30.2% |
| 2022 Q2 | 4.64 Billion TWD | 46.06% |
| 2021 Q1 | 3.09 Billion TWD | -39.71% |
| 2021 FY | 3.63 Billion TWD | -29.15% |
| 2021 Q3 | 3.15 Billion TWD | -4.73% |
| 2021 Q4 | 3.63 Billion TWD | 14.99% |
| 2021 Q2 | 3.31 Billion TWD | 7.27% |
| 2020 FY | 5.12 Billion TWD | 31.83% |
| 2020 Q1 | 3.78 Billion TWD | -2.55% |
| 2020 Q2 | 4.92 Billion TWD | 30.02% |
| 2020 Q3 | 4.65 Billion TWD | -5.43% |
| 2020 Q4 | 5.12 Billion TWD | 10.02% |
| 2019 Q1 | 3.68 Billion TWD | -0.76% |
| 2019 Q2 | 4.16 Billion TWD | 12.91% |
| 2019 Q3 | 3.67 Billion TWD | -11.74% |
| 2019 Q4 | 3.88 Billion TWD | 5.84% |
| 2019 FY | 3.88 Billion TWD | 4.67% |
| 2018 FY | 3.71 Billion TWD | 4.24% |
| 2018 Q4 | 3.71 Billion TWD | 7.81% |
| 2018 Q3 | 3.44 Billion TWD | -20.28% |
| 2018 Q2 | 4.32 Billion TWD | 32.04% |
| 2018 Q1 | 3.27 Billion TWD | -8.15% |
| 2017 Q1 | 3.48 Billion TWD | -7.37% |
| 2017 FY | 3.56 Billion TWD | -5.39% |
| 2017 Q4 | 3.56 Billion TWD | 5.57% |
| 2017 Q2 | 4.5 Billion TWD | 29.13% |
| 2017 Q3 | 3.37 Billion TWD | -25.08% |
| 2016 Q1 | 4.35 Billion TWD | -0.8% |
| 2016 FY | 3.76 Billion TWD | -14.25% |
| 2016 Q3 | 3.76 Billion TWD | -28.69% |
| 2016 Q4 | 3.76 Billion TWD | 0.16% |
| 2016 Q2 | 5.27 Billion TWD | 21.02% |
| 2015 Q3 | 4.11 Billion TWD | -3.85% |
| 2015 FY | 4.39 Billion TWD | 165.89% |
| 2015 Q4 | 4.39 Billion TWD | 6.84% |
| 2015 Q2 | 4.27 Billion TWD | 18.09% |
| 2015 Q1 | 3.62 Billion TWD | 119.18% |
| 2014 Q4 | 1.65 Billion TWD | 25.46% |
| 2014 Q2 | 2.15 Billion TWD | 58.95% |
| 2014 Q1 | 1.35 Billion TWD | -3.89% |
| 2014 FY | 1.65 Billion TWD | 17.33% |
| 2014 Q3 | 1.31 Billion TWD | -38.78% |
| 2013 Q4 | 1.4 Billion TWD | 22.88% |
| 2013 Q3 | 1.14 Billion TWD | -34.58% |
| 2013 Q2 | 1.75 Billion TWD | 52.73% |
| 2013 Q1 | 1.14 Billion TWD | 1.84% |
| 2013 FY | 1.4 Billion TWD | 25.02% |
| 2012 Q1 | 938.7 Million TWD | -4.64% |
| 2012 FY | 1.12 Billion TWD | 14.41% |
| 2012 Q2 | 1.42 Billion TWD | 52.18% |
| 2012 Q3 | 1.05 Billion TWD | -26.13% |
| 2012 Q4 | 1.12 Billion TWD | 6.73% |
| 2011 Q2 | 1.18 Billion TWD | 43.7% |
| 2011 FY | 984.4 Million TWD | 4.58% |
| 2011 Q1 | 826.76 Million TWD | -12.17% |
| 2011 Q4 | 984.4 Million TWD | 13.53% |
| 2011 Q3 | 867.08 Million TWD | -27.02% |
| 2010 FY | 941.33 Million TWD | -16.64% |
| 2010 Q4 | 941.33 Million TWD | 0.0% |
| 2009 FY | 1.12 Billion TWD | 34.18% |
| 2008 FY | 841.6 Million TWD | 11.77% |
| 2007 FY | 752.99 Million TWD | -4.18% |
| 2006 FY | 785.84 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | -27.218% |
| Maywufa Company Ltd. | 794.91 Million TWD | -388.342% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | -186.032% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 75.208% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -7562.665% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | -7.907% |
| PhytoHealth Corporation | 79.84 Million TWD | -4761.559% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | -144.024% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 28.457% |
| PharmaEssentia Corporation | 3.32 Billion TWD | -16.884% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 70.782% |